ArticlePhysiological reports2026
Exploring Glycocalyx shedding markers: A comparative analysis of plasma markers among premenopausal and postmenopausal women.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The endothelial glycocalyx (eGC) is a protein-rich, hairlike structure covering the luminal surface of endothelial cells, vital for vascular health. Aging and cardiovascular disease (CVD) can compromise eGC integrity, potentially preceding conventional indicators of vascular dysfunction such as reduced endothelium-dependent vasodilation and increased arterial stiffness. SDC-1 and HS are key glycosaminoglycans and validated plasma biomarkers reflecting glycocalyx integrity. During menopause the decline in estrogen, a vascular-protective hormone, has been linked to increased glycocalyx degradation and decreased nitric oxide (NO) synthesis contributing to endothelial dysfunction. This study examined glycocalyx degradation in premenopausal females versus postmenopausal females (early and late stages). Resting plasma samples from premenopausal (n = 11), early-postmenopausal (n = 12) and late-postmenopausal women (n = 13) were analyzed via ELISA for SDC-1 and HS. Late postmenopausal females had significantly higher mean plasma HS concentrations compared to early postmenopausal and premenopausal groups (4049.9 ± 1595.4 vs. 3919.0 ± 999.2, 2986.4 ± 1493.7 ng/mL, p = 0.003). Conversely, SDC-1 levels were higher in premenopausal women (p = 0.036). No correlations were observed between these biomarkers and flow-mediated dilation (all, p > 0.05). Overall, results suggest eGC integrity varies across reproductive stages, emphasizing the need for further research into mechanisms and interventions to preserve vascular health in aging females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.